--- title: "Curanex Pharmaceuticals (CURX) news: reverse split" url: "https://aibio.space/companies/curanex-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CURX reverse split, class action, going concern, IPO and offering news: Curanex regains Nasdaq bid-price compliance after 1-for-20 reverse split." --- CURX Curanex Pharmaceuticals Inc NASDAQ · United States # Curanex Pharmaceuticals (CURX) news CURX reverse split, class action and going concern news Legal · 2026-10-19 ## [Curanex discloses two New York class actions tied to its August 2025 IPO](https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/) Curanex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents. ## Latest Curanex Pharmaceuticals news 1. 2026-08-20 Listings [Curanex regains Nasdaq bid-price compliance after 1-for-20 reverse split](https://aibio.space/news/curanex-regains-nasdaq-bid-price-compliance-after-1-20-reverse-split/) Curanex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days. 2. 2026-08-14 Distress [Curanex flags going-concern doubt with $2.94 million in cash at June 30](https://aibio.space/news/curanex-flags-going-concern-doubt-2-94-million-cash-june-30/) Curanex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses. 3. 2025-09-24 Financings [Curanex repays $400,000 in loans from its CEO's wife weeks after its IPO](https://aibio.space/news/curanex-repays-400-000-loans-ceos-wife-weeks-after-ipo/) Curanex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027. 4. 2025-09-12 Financings [Curanex Pharmaceuticals raises $2,250,000 more as IPO underwriters exercise option](https://aibio.space/news/curanex-pharmaceuticals-raises-2-250-000-more-ipo-underwriters/) Dominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000. 5. 2025-08-27 Financings [Curanex raises $15 million in IPO, then $2.25 million more from overallotment](https://aibio.space/news/curanex-raises-15-million-ipo-then-2-25-million-more-overallotment/) Curanex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis. ## Curanex Pharmaceuticals at a glance - **Ticker**: CURX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $2.9 million ### Related companies - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) NASDAQ: RNAZ - [iBio](https://aibio.space/companies/ibio/) NASDAQ: IBIO - [Scilex Holding](https://aibio.space/companies/scilex/) NASDAQ: SCLX - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI - [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST - [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC ### Also on NASDAQ - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) RNAZ - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR - [Opus Genetics](https://aibio.space/companies/opus-genetics/) IRD - [MannKind](https://aibio.space/companies/mannkind/) MNKD - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR - [Aspire-Lakewood Holdings](https://aibio.space/companies/aspire-lakewood/) ASBP ## Curanex Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$3.0 million](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | | | Net income (loss) | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | [-$361,506](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | | Cash from operations | [-$10.5 million](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | [-$555,575](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | | Cash and equivalents | [$5.0 million](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Curanex Pharmaceuticals Did Curanex Pharmaceuticals do a reverse stock split? Our latest story on this, dated Aug 20, 2026: "Curanex regains Nasdaq bid-price compliance after 1-for-20 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curanex-regains-nasdaq-bid-price-compliance-after-1-20-reverse-split/). Is there a class action against Curanex Pharmaceuticals? Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/). Has Curanex Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Aug 14, 2026: "Curanex flags going-concern doubt with $2.94 million in cash at June 30". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curanex-flags-going-concern-doubt-2-94-million-cash-june-30/). When did Curanex Pharmaceuticals go public? Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/). Has Curanex Pharmaceuticals raised money recently? Our latest story on this, dated Oct 19, 2026: "Curanex discloses two New York class actions tied to its August 2025 IPO". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/). What is the ticker symbol of Curanex Pharmaceuticals? Curanex Pharmaceuticals Inc trades under the ticker CURX on NASDAQ. Where is Curanex Pharmaceuticals listed? Curanex Pharmaceuticals Inc is listed on NASDAQ. What is the SEC CIK of Curanex Pharmaceuticals? The SEC Central Index Key (CIK) for Curanex Pharmaceuticals Inc is 2025942. Its filings are on SEC EDGAR. How many shares does Curanex Pharmaceuticals have outstanding? 31,364,812 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Curanex Pharmaceuticals listed under? Our directory records Curanex Pharmaceuticals Inc under United States. What does Curanex Pharmaceuticals do? Our directory classifies Curanex Pharmaceuticals Inc as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Curanex Pharmaceuticals? The ISIN recorded for Curanex Pharmaceuticals Inc is US23126K3041. Does aibio.space cover Curanex Pharmaceuticals? aibio.space lists Curanex Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Curanex Pharmaceuticals incorporated? SEC records list its state or country of incorporation as NV. Is Curanex Pharmaceuticals profitable? Curanex Pharmaceuticals Inc reported a net loss of $4.2 million for the fiscal year ended Dec 31, 2025, and used $10.5 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Curanex Pharmaceuticals Members talk about Curanex Pharmaceuticals (CURX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Curanex Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-19 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) 2. 2026-09-14 Class action The company says Robert Lovett filed another putative securities class action. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) 3. 2026-09-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226041546/form8-k.htm) 4. 2026-08-20 Reverse split A one-for-twenty reverse split took effect to address minimum bid-price compliance. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm) 5. 2026-08-17 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm) 6. 2026-08-14 Going concern The interim report disclosed unresolved substantial doubt and inadequate twelve-month cash resources. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/form10-q.htm) 7. 2026-07-23 Class action The company says Daymond Morales and others filed a putative securities class action. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) 8. 2026-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226021658/form8-k.htm) 9. 2026-05-05 Listing notice Nasdaq granted an additional 180-day period, until 2026-11-02, to regain bid-price compliance; the company later reported that it had regained compliance. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226021658/form8-k.htm) 10. 2026-03-30 Going concern Management concluded earlier substantial doubt was alleviated in its annual report. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/form10-k.htm) 11. 2026-03-01 Leadership Continued-service employment agreements for the chief executive and chief operating officer took effect. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/form8-k.htm) 12. 2026-01-01 Leadership Wanjun Zhang became chief financial officer and treasurer under a consulting agreement. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226000358/form8-k.htm) 13. 2025-12-31 Leadership Haiyan Yang resigned as chief financial officer and treasurer, without a reported disagreement. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226000358/form8-k.htm) 14. 2025-11-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225023703/formnt10-q.htm) 15. 2025-11-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225023710/form10-q.htm) 16. 2025-11-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225021028/form8-k.htm) 17. 2025-11-05 Listing notice Nasdaq notified the company of minimum bid-price noncompliance; the matter was subsequently closed. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225021028/form8-k.htm) 18. 2025-09-25 Financing An 8-K reports 28,312 shares issued to settle an earlier subscription; the annual report gives a different issuance date. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/form8-k.htm) 19. 2025-09-24 Restructuring Curanex prepaid the second related-party note. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/form8-k.htm) 20. 2025-09-23 Restructuring Curanex prepaid the first of its two related-party notes. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/form8-k.htm) 21. 2025-09-12 Financing The full underwriter over-allotment purchase closed, adding $2.25 million gross. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225013167/form8-k.htm) 22. 2025-09-12 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225013167/ex99-1.htm) 23. 2025-08-27 Financing Curanex closed its initial public offering for $15 million gross. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225012404/form8-k.htm) 24. 2025-08-26 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/ex99-1.htm) 25. 2025-08-25 Financing Curanex signed the underwriting agreement for its initial public offering. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/form8-k.htm) 26. 2025-05-21 Financing The company received a further $200,000 loan from its secretary. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/form8-k.htm) 27. 2025-02-04 Financing The company received a $200,000 related-party loan from its secretary. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225015986/form8-k.htm) 28. 2024-11-19 Reverse split The annual report describes approval of a three-for-five reverse split effective on this date. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/form10-k.htm) ## Investor questions about Curanex Pharmaceuticals ### Is the earlier Nasdaq bid-price deficiency still open? Curanex reported that the matter was closed after Nasdaq confirmed compliance on 2026-09-03. This does not guarantee future compliance. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226041546/form8-k.htm) ### How much cash did Curanex report? It reported $2,938,463 in cash and cash equivalents at 2026-06-30. This is a historical balance, not a current daily cash figure. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/form10-q.htm) ### How long did management say cash would last? Management said cash would not cover at least twelve months from issuance of the interim statements. It did not give an exact exhaustion date. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/form10-q.htm) ### Did the latest interim report contain a going-concern warning? Yes. Management disclosed substantial doubt and said its plans did not alleviate it. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/form10-q.htm) ### Did Curanex complete a reverse split? It implemented a one-for-twenty reverse split effective on 2026-08-20. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm) ### How much did the original IPO raise before costs? The initial closing raised $15 million gross. Later option-exercise proceeds were additional. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315225012404/form8-k.htm) ### Are securities class actions disclosed? The company disclosed two preliminary putative securities class actions. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) ### Do the disclosed complaints assert company fraud? The issuer says neither complaint asserts a fraud claim against the company. This describes the issuer disclosure rather than an independent complaint review. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) ### Who audits Curanex? The latest annual audit report is signed by Kreit & Chiu CPA LLP. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226013677/form10-k.htm) ### Does the employee-plan registration establish fresh cash financing? No. It registers remaining shares issuable under an incentive plan and does not announce a cash offering. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047616/forms-8.htm) ### Who are the largest disclosed common holders? The latest opened ownership table reports overlapping beneficial interests for Jun Liu and Dian Ying Jing and a separate interest for Chang Liu. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226030447/formdef14c.htm) ### Are pre-split outstanding shares a current share count? No. The quarterly cover reports a dated pre-split count; the later corporate-action report estimates the adjusted amount. [Source](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CURX on TradingView](https://www.tradingview.com/symbols/NASDAQ-CURX/). ## SEC filings and registration - **SEC name**: Curanex Pharmaceuticals Inc - **CIK**: 2025942 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CURX (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2 JERICHO PLAZA,, JERICHO, NY, 11753 - **Phone**: 718-673-6078 - **Shares outstanding**: 31,364,812 as of 2026-08-14 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226047614/form8-k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226041546/form8-k.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/2025942/000149315226038145/form10-q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226022898/form8-k.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/2025942/000149315226022892/form10-q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226021658/form8-k.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/2025942/000149315226014815/form8-k.htm) filed 2026-04-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002025942), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Curanex Pharmaceuticals Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CURX, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Curanex Pharmaceuticals Inc - **Ticker**: CURX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US23126K3041 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CURX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/curanex-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Curanex Pharmaceuticals (CURX) news: reverse split", 2026-10-31, https://aibio.space/companies/curanex-pharmaceuticals/